Home › Funds › GENEVA CAPITAL MANAGEMENT LLC › TECH

GENEVA CAPITAL MANAGEMENT LLC position in TECH

BIO-TECHNE CORP · Health Care

GENEVA CAPITAL MANAGEMENT LLC reported holding 884,168 shares of TECH (BIO-TECHNE CORP) in its Q3 2026 13F filing — a position valued at US$64.1M, representing 1.79% of its reported portfolio and ranking #19 among its reported holdings. GENEVA CAPITAL MANAGEMENT LLC has disclosed TECH holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)884.17K sh
Reported value held$64.08M
Portfolio Weight1.79%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How GENEVA CAPITAL MANAGEMENT LLC's TECH position evolved

GENEVA CAPITAL MANAGEMENT LLC first disclosed a stake in TECH in Q3 2023 at 1,069,934 shares (US$72.8M). The position peaked in Q3 2024 at 1,104,310 shares, worth US$88.3M. Across 13 filings, GENEVA CAPITAL MANAGEMENT LLC increased the stake 6 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 884,168 shares valued at US$64.1M — a reduction of -127,909 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.07M $72.83M New
Q4 2023 1.08M $83.28M Add
Q1 2024 1.08M $76.02M Hold
Q2 2024 1.09M $77.90M Add
Q3 2024 1.10M $88.27M Add
Q4 2024 1.09M $78.51M Reduce
Q1 2025 1.10M $64.42M Add
Q2 2025 1.19M $60.97M Add
Q3 2025 1.19M $65.92M Hold
Q4 2025 1.09M $64.13M Reduce
Q1 2026 1.24M $64.96M Add
Q2 2026 1.01M $71.50M Reduce
Q3 2026 884.17K $64.08M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TECH and 13F data

TECH (BIO-TECHNE CORP) is a Health Care company. 27 other funds we track also report a position in TECH — the largest reported positions include HBK INVESTMENTS L P (US$482.2M), Ruane Cunniff & Goldfarb (Sequoia) (US$236.6M), SNYDER CAPITAL MANAGEMENT L P (US$223.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TECH

All TECH fund holders →

FAQ

How long has GENEVA CAPITAL MANAGEMENT LLC held TECH?

GENEVA CAPITAL MANAGEMENT LLC has disclosed TECH holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is GENEVA CAPITAL MANAGEMENT LLC's current position in TECH?

As of Q3 2026, GENEVA CAPITAL MANAGEMENT LLC holds 884.17K shares of TECH (BIO-TECHNE CORP), valued at $64.08M, representing 1.79% of its reported portfolio and ranking #19.

Has GENEVA CAPITAL MANAGEMENT LLC been buying or selling TECH?

In the latest 13F filing (Q3 2026), GENEVA CAPITAL MANAGEMENT LLC reduced its position in TECH. The position peaked in Q3 2024 at 1.10M shares.

Which other funds hold TECH?

Other major institutional holders of TECH include HBK INVESTMENTS L P, Ruane Cunniff & Goldfarb (Sequoia), SNYDER CAPITAL MANAGEMENT L P, among 27 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.